Inhibition of Bruton tyrosine kinase in patients with severe COVID-19
There has been concern about drug shortages during the COVID-19 pandemic. The CLL Society investigated these concerns and has been reassured that, at least for ibrutinib, there will be no impacts to the product supply.
Related posts